•
RA
RAPP
Rapport Therapeutics, Inc. Common Stock
yahooPHARMACEUTICAL PREPARATIONS
--
Price Chart
Market Cap
1.26B
Volume
316.30K
52W High
$42.27
52W Low
$6.43
Open
$0.00
Prev Close
$25.97
Day Range
0.00 - 0.00
About Rapport Therapeutics, Inc. Common Stock
Rapport Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovery and development of transformational small-molecule medicines for patients suffering from central nervous system disorders. Its foundational science has elucidated the complexities of neuronal receptor biology and enables the company to map and target certain neuronal receptor complexes. Neuronal receptors are complex assemblies of proteins, comprising receptor principal subunits and their receptor-associated proteins (RAPs), the latter of which play crucial roles in regulating receptor expression and function.
Latest News
Rapport Announces Pricing of Public Offering of Common Stock
Benzinga•Sep 10
Analysts Can't Get Enough of These Little-Known Biopharma Stocks
Investing.com•Jun 12
Rapport Therapeutics Hosts Investor and Analyst Day; Provides Corporate Updates
GlobeNewswire Inc.•Jun 2
Rapport Therapeutics to Present Data at the 2025 American Academy of Neurology Annual Meeting
GlobeNewswire Inc.•Mar 21
Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS Disorders
GlobeNewswire Inc.•Jan 9
Rapport Therapeutics to Present at Upcoming Epilepsy Medical Conferences
GlobeNewswire Inc.•Sep 5
Rapport Therapeutics to Present at 22nd Annual Morgan Stanley Global Healthcare Conference and TD Cowen’s 4th Annual Novel Mechanisms in Neuropsychiatry Summit
GlobeNewswire Inc.•Aug 29
Wall Street Breakfast: The Week Ahead
Seeking Alpha•Jun 30